Device Trial Radar · NCT03640988
The Effects of High Energy Acoustic Shock Wave Therapy on Local Skin Perfusion and DFUs
Last checked: Nov 19, 2026Latest source record: Nov 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Apr 25, 2019
Primary completion
Jan 3, 2021
Study completion Jan 3, 2021
Sponsor
- Lead sponsor
- SANUWAVE, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 21, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational, single-arm, on-label study. This clinical study will be conducted at up to 2 sites with a total of 10 subjects per site. All subjects will receive standard of care treatment which includes DFU treatments with the dermaPACE device.
Conditions
- Diabetic Foot Ulcer
Interventions
dermaPACEDevice
Shockwave application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Skin perfusion, effect on oxygenation level, by visitTime frame: 10 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital
Newark, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.